A clinical trial is testing whether an existing drug could benefit patients with Alzheimer’s disease, in hopes of making ...
The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare ...
Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...
Posterial Cortical Atrophy, sometimes called Benson’s disease, is a rare degenerative brain condition that affects the back ...
As our family members age, we worry. We worry about their physical health and potential cognitive declines. If you are ...
In the heart of Seattle, some of the world’s most brilliant minds study the brain at the Allen Institute, where researchers ...
A new study distinguishes between two distinct phases of Alzheimer's disease: an early, 'stealth' one without symptoms, and a ...
U.K. regulators will reportedly recommend the NHS not cover Eli Lilly’s (LLY) donanemab for the treatment of early ...
Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to ...
A SECOND “game-changing” Alzheimer’s drug shown to slow the progression of the disease has been approved in the UK. Donanemab, developed by pharmaceutical giant Eli Lilly, was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback